{"doi":"10.1016/j.gore.2025.101797","title":"Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma","abstract":"Objectives: To report a case of complete response to trastuzumab-deruxtecan (T-DXd) in a patient with HER2-positive stage IVB uterine carcinosarcoma, and to contextualize this within evolving therapy for HER2-positive gynecologic malignancies. Methods: We present the clinical course of a 62-year-old woman with a history of multiple prior malignancies, diagnosed with stage IVB uterine carcinosarcoma exhibiting HER2 overexpression. Following optimal cytoreductive surgery and first-line carboplatin, paclitaxel, and trastuzumab, the patient developed platinum-resistant recurrence. She was subsequently treated with T-DXd, and received serial imaging and clinical monitoring. Results: The patient achieved a partial response by cycle 4 of T-DXd, with subsequent scans demonstrating a complete response with no evidence of disease. She has successfully completed 21 cycles of T-DXd with minimal toxicity, aside from a reversible acute kidney injury and a small pleural effusion, both resolving without sequelae. The patient remains asymptomatic and continues therapy without any cardiopulmonary complications. Conclusions: This case highlights the efficacy of T-DXd for HER2-positive, platinum-resistant uterine carcinosarcoma, even when previously treated with Trastuzumab. Highly durable, complete response with manageable toxicity was achieved, underscoring the promise of T-DXd.","journal":"Gynecologic Oncology Reports","year":2025,"id":541580,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9485,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":480613,"name":"Amma Asare","orcid":"0000-0002-4865-6864","position":1,"is_corresponding":false},{"id":1430280,"name":"Jeanne Dockery","orcid":null,"position":2,"is_corresponding":false},{"id":1112057,"name":"Nadia Hameed","orcid":null,"position":3,"is_corresponding":false},{"id":292265,"name":"Travis T. Sims","orcid":"0000-0003-1975-0795","position":4,"is_corresponding":false},{"id":1349266,"name":"Michael Kim","orcid":"0000-0002-2813-2123","position":0,"is_corresponding":true}],"reference_count":7,"raw_metadata":null,"created_at":"2026-07-19T02:52:47.161928Z","pmid":"40687920","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}